oru.sePublikationer
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients
Karolinska Univ Hosp, Dept Haematol, Stockholm, Sweden..
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.;Canc Therapy Res Ctr, San Antonio, TX USA..
Fac Hosp Brno, Dept Internal Med Haematooncol, Brno, Czech Republic..
Johannes Gutenberg Univ Mainz, D-55122 Mainz, Germany..
Show others and affiliations
2015 (English)In: British Journal of Haematology, ISSN 0007-1048, E-ISSN 1365-2141, Vol. 170, no 1, 40-49 p.Article in journal (Refereed) Published
Abstract [en]

There are limited data on retreatment with monoclonal antibodies (mAb) in patients with chronic lymphocytic leukaemia (CLL). In a pivotal study, ofatumumab (human anti-CD20 mAb) monotherapy demonstrated a 47% objective response rate (ORR) in fludarabine refractory CLL patients. From this study, a subset of 29 patients who had at least stable disease and then progressed were retreated with eight weekly ofatumumab infusions (induction treatment period), followed by monthly infusions for up to 2years (maintenance treatment period). The ORR after 8weeks of induction retreatment was 45% and 24% had continued disease control after maintenance at 52weeks. Efficacy and safety of the retreated patients were compared with their initial results in the pivotal study. Response duration was 241months vs. 68months; time to next therapy was 148months vs. 123months; and progression-free survival was 74months vs. 79months (medians). Upon retreatment, 72% had infusion reactions, mostly Grade 1-2. Three patients had fatal infections. In summary, ofatumumab retreatment and maintenance therapy was feasible in patients with heavily pretreated CLL and appeared to result in more durable disease control than initial ofatumumab treatment in this subset of patients who may have a more favourable disease profile.

Place, publisher, year, edition, pages
2015. Vol. 170, no 1, 40-49 p.
Keyword [en]
ofatumumab, chronic lymphocytic leukaemia, anti-CD20 monoclonal antibody, retreatment, maintenance
National Category
Hematology
Identifiers
URN: urn:nbn:se:oru:diva-56556DOI: 10.1111/bjh.13380ISI: 000356716500007PubMedID: 25825041OAI: oai:DiVA.org:oru-56556DiVA: diva2:1082774
Available from: 2017-03-17 Created: 2017-03-17 Last updated: 2017-11-29Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Kozlowski, PiotrRizzi, RitaDyer, Martin J. S.
By organisation
Örebro University Hospital
In the same journal
British Journal of Haematology
Hematology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 3 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf